- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
What Is Human Serum Albumin and How It Drives Modern Medicine
Feb 25, 2026
Liberty Health Sciences and iHeartJane Partner to Offer Patients a Real-Time Inventory Online Shopping Experience
Jan 22, 2020
COVID-19 Fallout Drives Major Increases for Driven's Online Cannabis Sales
Mar 17, 2020
Asia Pacific Starch Softgel Capsules Market Size, Share, Demand, Analysis and Forecast To 2027 | Hunan Er-Kang Pharmaceutical Co. Ltd,Softcaps,Fuji Capsule Co. Ltd.,Aenova Holding GmbH,Sirio Pharma Co. Ltd.
Oct 15, 2020
OTC Drug and Dietary Supplement Market Outlook, Geographical Segmentation, Industry Size & Share, Comprehensive Analysis to 2027
Sep 09, 2020
Drugmaker Sanofi to raise over $11 billion by selling its U.S. partner Regeneron shares
May 27, 2020
Applied BioMath, LLC Announces Collaboration with Northern Biologics
Apr 22, 2020
Follow us on
